Donor-derived AML following allogeneic transplantation is a rare but well documented late complication of allogeneic transplantation. 1, 2 Cases may present as frank leukaemia or with an antecedent history of myelodysplastic syndrome, and case studies have been published after BM, peripheral blood progenitor cell 3 and umbilical SCT. 4 However, initial presentation with myelofibrosis has not been previously reported.
A 36-year-old woman of Indian Asian ethnic origin presented with Philadelphia-positive CML (chronic phase) in 1994. She was treated with interferon-a before proceeding to an allogeneic BMT in 1996 from her HLA-matched sister. The conditioning regimen was CY (120 mg/kg) and TBI (14.4 Gy; total dose given over 4 days). Post-transplant complications included acute (grade II) GVHD progressing to chronic GVHD with extensive sclerodermatous changes (including oral involvement) and partial alopecia. Following the development of CYA-associated microangiopathy, this drug was stopped on day þ 56. Prednisolone, commenced initially as treatment for aGVHD, was continued and attempts to control the chronic GVHD with azathioprine, mycophenolate mofetil and CYA met with limited success. Control was eventually obtained with a combination of azathioprine (up to 100 mg b.i.d), prednisolone (up to 60 mg daily) and extracorporeal photopheresis, with the severity of the chronic GVHD necessitating the maintenance immunosuppression with azathioprine.
In June 2005, the patient re-presented with fever, and a pancytopenia (Hb 6.7 g per 100 ml, WCC 1.4 Â 10 9 /l, plts 51 Â 10 9 /l) and a normal blood film. BM aspirate was hypoparticulate, and trephine biopsy showed grade III reticulin fibrosis, 5 (grade II by European consensus classification 6 ; Figure 1 ) with mild dyserythopoiesis, but no excess of blasts. Cytogenetic analysis (including FISH for BCR/ABL1) was normal. The patient was not considered to have primary myelofibrosis as there was no hepatosplenomegaly (confirmed by abdominal CT) with an absence of the peripheral blood features of primary myelofibrosis. 7 Of note was the presence of a reduced number of morphologically normal megakaryocytes in this and subsequent trephine biopsies.
Investigations failed to confirm any infective process and excluded other causes of marrow fibrosis, although autoantibody screening confirmed a weak-positive fine speckled antinuclear antibody and a positive rheumatoid factor of 140 i.u./ml (normal range: 0-40). At this time, the GVHD was well controlled and, in view of the pancytopenia, the azathioprine was withdrawn.
Given the positive autoantibody screen, a diagnosis of autoimmune myelofibrosis was considered 8 and prednisolone (1 mg/kg) was commenced. The response was immediate, with resolution of fever and symptomatic relief. The haematology improved (neutrophils 0.3 to 41.0 Â 10 9 /l over 18 days) with a decreased red cell transfusion requirement, but the thrombocytopenia persisted (o20 Â 10 9 /l). A BM biopsy performed 2 weeks after starting prednisolone remained hypocellular and fibrotic on trephine biopsy (dry tap on aspirate). A further marrow examination 4 months after commencing prednisolone demonstrated dyshaematopoiesis, but with markedly reduced fibrosis (minimal focal increase) ( Figure 2 ) and no excess of blasts.
Given the response to prednisolone and the reports of thalidomide use in primary myelofibrosis, 9 thalidomide was commenced in October 2005 as a potential steroid-sparing agent and to further improve cytopenias. However, by late October 2005, blast cells had appeared in the peripheral blood. BM aspirate and trephine confirmed AML (71% blasts on aspirate with morphology consisting of a basophilic cytoplasm with granulation, a high nuclear to cytoplasm ratio and no evidence of dysplasia and minimal maturation; immunophenotypes were CD34 þ , CD13 þ , CD33 þ and CD117 þ ). Cytogenetic analysis demonstrated monosomy 7 with an unbalanced translocation between chromosomes 17 and 22, and continued absence of the Philadelphia chromosome and BCR/ABL1 rearrangement by both FISH and cytogenetics. Short tandem repeat sequences were examined at 16 polymorphic loci in the blast cells. Of these, 10 were informative (i.e. alleles not homozygous between donor and recipient). Calculations demonstrated the donor origin of the blasts (99% donor chimerism).
The patient was treated with intensive induction chemotherapy ('FLAG-Ida' regimen), and morphological and cytogenetic remission of the leukaemia within the context of donor-derived haematopoiesis was confirmed on repeat BM examination. Despite an international unrelated donor panel search, no HLA-matched unrelated donors could be identified (the ethnic origin of the patient being a significant factor in this respect). The original donor remained well and there was no evidence of myeloid malignancy on BM examination. The patient's remaining siblings were also considered but were not HLA matched. Although it was thought unlikely that any significant GVL effect would result, a second transplant was performed from the original donor in /l by day þ 14). However, by day þ 122, blasts had appeared in the peripheral blood with a return of the cytogenetic abnormalities and evidence of karyotypic evolution involving chromosomes 5, 9 and 21. Thereafter, management was palliative and the patient died at day þ 140 post transplant.
In conclusion, we describe a case in which a donorderived acute leukaemia presented with marrow fibrosis and systemic symptoms. Other causes of secondary myelofibrosis, including the previous CML and autoimmune myelofibrosis, were considered in the differential diagnosis but were subsequently excluded by the clinical course and laboratory investigations. The causes of the donor-derived myeloid malignancy in this case are uncertain, but the prolonged immunosuppression and the cytotoxic exposure to azathioprine might have played a part.
This case also illustrates the failure of a reduced-intensity conditioning transplant from the original donor, despite the achievement of CR before transplant, prompt trilineage engraftment and CR 3 months post transplant. Previous reports suggest some success with second transplants. Letter to the Editor
